3.6 Infusion Monitoring & Acute Reaction Differential Management
Key Takeaways
- Monitoring intervals during and after administration are product-specific and are documented against the product instructions; a familiar blood-component monitoring schedule is not a valid substitute.
- For any reaction, pause or stop as directed, maintain access, assess airway/breathing/circulation, activate the emergency pathway, preserve the product/records, and treat the diagnosed syndrome under orders.
- Differentiate allergy/anaphylaxis, hemolysis, bacterial contamination, volume overload, acute lung injury, citrate/DMSO effects, and disease- or therapy-related deterioration using timing, examination, labs, and product characteristics.
- Bradycardia with flushing and nausea during a thawed cryopreserved product suggests DMSO-mediated histamine release and vagal stimulation, whereas hypertension with jugular venous distension and bibasilar crackles suggests circulatory overload from the infused volume.
1. Monitoring During and After Administration
Obtain the protocol-defined baseline, including symptoms, temperature, blood pressure, pulse, respiratory rate, oxygen saturation, access assessment, and other monitoring indicated by product volume, DMSO, ABO mismatch, cardiac risk, or prior reaction. Remain able to observe and respond throughout administration. Frequency may be more intensive at initiation and after each bag, but the guide does not replace the label or center's vital-sign schedule.
Watch for fever/rigors, flushing, urticaria, angioedema, wheeze/stridor, dyspnea, chest or back pain, nausea/vomiting, bradycardia or tachyarrhythmia, blood-pressure change, hypoxia, hemoglobinuria, volume overload, neurologic change, and access-site leakage. Trend cumulative volume and DMSO across bags. Post-administration observation duration is individualized to reaction, product, setting, and protocol.
2. Acute Reaction Priorities and Differential
For a severe reaction, stop or pause administration as directed, preserve the product and tubing for investigation, maintain vascular access with a compatible solution, assess airway/breathing/circulation, call the emergency and transplant/cellular team, and verify the product/patient match. Do not restart without an authorized decision.
| Pattern | Key clues | Immediate nursing focus |
|---|---|---|
| Anaphylaxis | Rapid airway swelling, wheeze/stridor, urticaria, hypotension | Emergency response and IM epinephrine per anaphylaxis protocol; airway/oxygen/circulatory support. Antihistamine or corticosteroid is adjunctive, not a substitute for epinephrine. |
| DMSO-related reaction | Garlic/creamed-corn odor, nausea, flushing, pressure change, bradycardia, dyspnea | Pause/slow per order, supportive care, and evaluate severity; symptomatic bradycardia follows the emergency protocol. |
| Hemolysis/ABO reaction | Fever/chills, pain, hypotension, red urine, laboratory hemolysis | Stop, verify identity/compatibility, notify transfusion/cell lab, send the required specimens/product, and support kidney/hemodynamic status per orders. |
| Contamination/sepsis | Rigors, high fever, rapidly progressive shock | Cultures from patient and product as directed, immediate antimicrobial/sepsis care, and preservation/reporting of the bag and tubing. |
| Volume or pulmonary reaction | Dyspnea/hypoxia with hypertension/overload clues or noncardiogenic pattern | Stop, support oxygenation/hemodynamics, and differentiate overload, lung injury, anaphylaxis, sepsis, and cardiac disease before assuming diuresis. |
| Mechanical/product issue | Leak, occlusion, aggregate, wrong rate, extravasation, lost product | Stop manipulation, clamp/contain safely, preserve sterility, and contact the cell lab/medical director for the approved recovery or deviation process. |
After any significant reaction, document timing, bag/product identifiers, volume/cells delivered, assessment, actions, response, notifications, specimens, and disposition. Complete the required institutional, manufacturer, transfusion-service, FDA, or accreditation reports as applicable.
3. Discriminating the Look-Alike Cardiopulmonary Emergencies
Dyspnea during or shortly after a cellular product is the situation that most often requires the nurse to reason faster than the laboratory. Several syndromes present inside the same window and are separated almost entirely by bedside findings, because confirmatory testing arrives long after the first ten minutes of care have been decided.
Transfusion-associated circulatory overload (TACO) is a hydrostatic problem: delivered volume exceeds what the circulation can accommodate. Look for hypertension, jugular venous distension, bibasilar crackles, a widened pulse pressure, and rapidly positive fluid balance. It favors recipients with cardiomyopathy, renal impairment, small body size, or a large-volume fresh marrow product, and oxygenation improves with upright positioning and ordered diuresis.
Transfusion-related acute lung injury (TRALI) is a permeability problem in the pulmonary microvasculature. Look for hypotension or an unchanged blood pressure, fever, and bilateral infiltrates without jugular venous distension or other volume-overload signs. Diuresis does not help and may harm; management is oxygenation and ventilatory support.
Anaphylaxis adds airway and skin involvement - stridor, wheeze, urticaria, angioedema - with hypotension, usually within minutes of starting. DMSO-mediated reaction produces flushing, nausea, the characteristic odor, and bradycardia rather than tachycardia, with clear lungs.
| Discriminator | TACO | TRALI | Anaphylaxis | DMSO effect |
|---|---|---|---|---|
| Blood pressure | Elevated | Low or unchanged | Low | Either direction |
| Fever | Absent | Common | Absent | Absent |
| Jugular venous distension | Present | Absent | Absent | Absent |
| Skin or airway signs | Absent | Absent | Prominent | Flushing only |
| Heart rate | Elevated | Elevated | Elevated | Often bradycardic |
| Response to diuresis | Improves | No benefit or harmful | No benefit | Not applicable |
Two habits prevent most missed reactions. First, anchor every finding to the patient's own baseline rather than to a population normal range: a rise from 96/58 to 118/70 mmHg is a meaningful change in someone who lives at the lower number, and 37.8 degrees Celsius matters in a patient who has been afebrile for a week. Second, reassess after every intervention rather than only at scheduled intervals, because a rate reduction, a position change, or a premedication dose creates a new baseline that must be measured before it can be trusted.
Volume tolerance is body-size dependent, so pediatric and small adult recipients reach a hazardous cumulative volume at a bag count that would be unremarkable in a larger patient. Track milliliters per kilogram alongside absolute volume and escalate the running total to the prescriber before the final bag rather than after the patient decompensates.
4. Post-Administration Handoff and Dose Accounting
Observation does not end when the bag empties. Before the patient leaves the monitored setting, reconcile and document three things: the total volume and DMSO delivered across all bags, the cell dose actually administered compared with the dose ordered, and any residual or lost product with its disposition. A bag that clotted, leaked, or was returned unfinished changes the delivered dose, which the transplant team needs when interpreting later engraftment kinetics or a manufacturing investigation.
Hand off the specific reaction history rather than a global "tolerated well." Name what happened, at what cumulative volume, what was given, and how the patient responded, because the next bag or the next product often reproduces the same physiology. For outpatient administration, confirm before discharge that the patient and caregiver can state which symptoms require an immediate return, who to call at any hour, and that transportation is available throughout the product-defined monitoring window.
Forty-five minutes into an autologous stem cell infusion, a 62-year-old patient with a history of cardiomyopathy develops sudden shortness of breath, a blood pressure spike from 124/76 to 178/102 mmHg, a heart rate of 115 bpm, jugular venous distention, and diffuse bibasilar crackles on lung auscultation. Pulse oximetry drops to 88% on room air. How should the nurse distinguish and manage this reaction?
Forty minutes into a thawed autologous stem cell infusion, one patient develops flushing, nausea, and bradycardia to 46 bpm with clear breath sounds and stable oxygen saturation. On another unit, a patient 30 minutes into a large-volume fresh allogeneic marrow infusion develops hypertension, jugular venous distension, and bibasilar crackles. Which interpretation best fits these two presentations?